NUXA Diagnostics
On-site molecular diagnostics for any disease.
The founders
PB
The company
NUXA Diagnostics is building an on-site molecular diagnostics platform that aims to detect the specific DNA or RNA of any disease in under 30 minutes. It uses a prokaryotic Argonaute protein guided by a short RNA sequence in an isothermal, one-pot reaction, so testing can happen in the field without complex lab equipment.
Central-lab results can take days and demand sample transport plus trained personnel; NUXA argues the same answers can be delivered on-site at a fraction of the cost of traditional PCR. With a reprogrammable guide, the company says a test for a new disease can be designed within days.
NUXA is a future spin-off from Wageningen University, applying a detection method inspired by the bacterial immune system to real-world testing. The company was founded in 2026 in Wageningen by Patrick Barendse and Daniël Besselink.
As a Wageningen University spin-out, the founding team is building on an academic base in one of Europe's strongest life-sciences hubs. We don't have detailed founder pedigrees here, but the spinout route suggests the technology is coming out of serious research rather than a pitch deck.
Who else is building in this space
Companies working on the same thing, at every stage.
Unicorn
Developing a new generation of nanopore-based electronic systems for analysis of single molecules
Unicorn
A clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to industrialize drug discovery
Scale-up
A company focused on the advancement of universal access to genomic information by delivering an affordable, scalable, and accurate genomic sequencing ecosystem that empowers both academic and clinical research applications
Scale-up
Develops diagnostic systems to reduce the cost and improve the efficacy of personalised medical treatments
Scale-up
Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies
Scale-up
Researches and develops technology for early-stage cancer screening
Thousands more founded every month.
Dealroom tracks new companies as they appear — founders, funding and signals, over the API or in the platform.